On September 10, 2026, a Phase 2 clinical trial update was recorded for research involving somatostatin analogues. The trial, titled "Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours," is registered under identifier NCT06345079.
According to the listing, the study is currently in the recruiting stage. The trial is designated Phase 2 and focuses on patients with mid-gut, hind-gut, and pancreatic neuroendocrine tumours who have undergone peptide receptor radionuclide therapy, known as PRRT. The registered title indicates the study is examining the cessation of somatostatin analogue treatment following PRRT in this patient population.
No outcome data, efficacy findings, or safety results have been reported as part of this update. The trial status reflects only that recruitment is ongoing at the time of this record. Somatostatin remains classified as an unapproved compound for research purposes in this context.
Readers interested in background information on somatostatin can consult the compound overview for further context.